Study S001875

Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07639021
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 233
Start: 2026-06-09
Primary completion: 2027-06-14
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:NNC0662-0419; DRUG:Semaglutide; DRUG:NNC0662-0419 Placebo; DRUG:Semaglutide placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1333-3475

Registered primary outcomes

Number of gastrointestinal adverse events [From week 0 to week 39]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.